Receptors Lecture Notes
Receptors Lecture Notes
Introduction
Presenter's name: Dr. Brendan Wilkins
Email: b.wilkins@unsw.edu.au
Source of material: University of New South Wales
Note: Material is subject to copyright
Learning Objectives
Define the concept of a receptor.
Explain the role receptors play in cellular functions.
Identify major protein families that are drug action sites.
Describe cellular locations and structural characteristics of each receptor family.
Discuss time scales for cellular changes induced by each receptor family.
Receptor Mechanism of Action = induce cellular signaling
Reception: An endogenous (hormone or neurotransmitter) or exogenous ligand binds to a receptor.
Transduction: The receptor transmits information across the cell membrane through interactions with intracellular proteins/molecules, leading to a signal transduction pathway.
Response: Effector proteins stimulate biological responses (e.g., muscle contraction).
Example of Receptor Mechanism of Action
1. Reception:
Example: When adrenaline (an endogenous ligand) is released into the bloodstream during a stress response, it binds to the beta-adrenergic receptors on cardiac muscle cells.
2. Transduction:
The binding of adrenaline to the beta-adrenergic receptor activates the receptor, which then interacts with intracellular G proteins. This leads to the activation of adenylate cyclase, which converts ATP to cyclic AMP (cAMP). cAMP acts as a second messenger in the signaling pathway, furthering the signal transduction by activating protein kinase A (PKA).
3. Response:
Activated PKA then phosphorylates various target proteins within the cell, leading to biological responses such as increased heart rate and contraction strength. This physiological change prepares the body to react to the stressor (known as the fight or flight response).
Types of Ligands
Endogenous Agonist: A ligand from within the body that activates the receptor (e.g., hormones, neurotransmitters).
Exogenous Agonist: A ligand from outside the body that activates the receptor (e.g., drugs like salbutamol).
Antagonist: A molecule that blocks the effects of an agonist on the receptor, keeping the receptor OFF.
Examples of Agonists and Antagonists
Agonists: Adrenaline, Salbutamol
Antagonists: Metoprolol
Drug Targets Overview
Receptor Drug Targets:
Ligand-gated ion channels
G protein-coupled receptors
Catalytic receptors
Nuclear receptors
Non-Receptor Drug Targets:
Transporters
Enzymes
Drug Targets Overview
Receptor Drug Targets:
Ligand-Gated Ion Channels:
These receptors allow ions (e.g., Na+, K+, Ca2+) to flow across the cell membrane when a ligand binds to them, leading to rapid cellular responses.
Example: The nicotinic acetylcholine receptor changes conformation when acetylcholine binds, permitting Na+ influx and triggering muscle contraction.
G Protein-Coupled Receptors (GPCRs):
Composed of seven transmembrane helices, GPCRs are involved in various signaling pathways and are highly diverse, with over 800 types identified in the human genome.
Example: The beta-adrenergic receptor activates a G protein upon binding to adrenaline, influencing processes like heart rate and smooth muscle contraction.
Catalytic Receptors:
These receptors have intrinsic enzyme activity and often dimerize upon ligand binding, facilitating the phosphorylation of specific proteins within the cell.
Types: Includes receptor tyrosine kinases (RTK), receptor serine/threonine kinases, cytokine receptors, receptor guanylyl cyclases, and receptor protein tyrosine phosphatases.
Example: Insulin receptor, a type of RTK, initiates a signaling cascade affecting glucose uptake and metabolism.
Nuclear Receptors:
Located inside the cell, these receptors bind to endogenous ligands and directly influence gene transcription after undergoing conformational changes.
Types:
Class I (e.g., glucocorticoids) respond to steroid hormones, while
Class II (e.g., thyroid hormones) respond to lipid ligands.
Example: Thyroid hormone receptors regulate metabolic processes by modulating gene expression for metabolism-related genes.
Non-Receptor Drug Targets:
Transporters:
Proteins that facilitate the movement of substrates across cell membranes, such as neurotransmitters.
They can be targets for drugs that inhibit or regulate neurotransmitter action in the central nervous system (CNS).
Example: Selective serotonin reuptake inhibitors (SSRIs) inhibit serotonin transporters to increase serotonin levels in the synaptic cleft, aiding in mood regulation.
Enzymes:
Proteins that catalyze biochemical reactions by lowering the activation energy.
Many drugs work as enzyme inhibitors to alter metabolic pathways.
Example: Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain.
Receptor vs. Non-Receptor Drug Targets
Receptor Drug Targets
Bind endogenous molecules and elicit signaling.
Non-Receptor Drug Targets
Do not bind endogenous molecules to initiate an intracellular signaling pathway; perform unique functions such as ion transport or catalysis.
Can be targeted with exogenous molecules to modulate their function
Example: Transporters involved in neurotransmitter regulation or pharmacokinetics of drugs.
Non-Receptor Drug Targets
Non-receptor drug targets are molecular entities that do not bind endogenous molecules to elicit a traditional signaling response but perform specific functions critical to various biological processes, including ion transport and catalysis. These targets can play significant roles in pharmacokinetics and neurotransmitter regulation.
Types of Non-Receptor Drug Targets:
Transporters:
Function: Proteins that facilitate the movement of substrates, such as ions and neurotransmitters, across cellular membranes. They are vital for maintaining the balance of neurotransmitters in the central nervous system (CNS) and can modulate receptor activity indirectly by affecting neurotransmitter levels.
Examples:
Selective Serotonin Reuptake Inhibitors (SSRIs): These drugs inhibit serotonin transporters, thereby increasing serotonin levels in the synaptic cleft and improving mood regulation in conditions like depression.
Dopamine Transporters (DAT): Targeted by certain stimulant medications, these transporters play a crucial role in regulating dopamine levels, which can affect mood and attention.
Enzymes:
Function: Enzymes catalyze biochemical reactions, lowering the activation energy required for these reactions and thereby facilitating metabolic processes. Drugs often target enzymes to alter or inhibit their activity, leading to desired therapeutic effects.
Examples:
Ibuprofen: An anti-inflammatory drug that inhibits cyclooxygenase (COX) enzymes, reducing production of inflammatory mediators and alleviating pain.
Neostigmine: An inhibitor of acetylcholinesterase, it increases the levels of acetylcholine in the neuromuscular junction, enhancing muscle contraction and improving conditions like myasthenia gravis.
Role of Non-Receptor Drug Targets in Pharmacotherapy:
Non-receptor targets are integral in drug design as they offer unique mechanisms that can complement receptor interactions. They are particularly important in developing medications that require modulation of substrate availability or alteration of cellular metabolism, thereby enhancing therapeutic outcomes. Understanding these targets allows for more precise strategies in managing diseases, especially those involving neurotransmission and metabolic disorders.
Drug Targets Percentages Condensed
1. Receptor Drug Targets (60-65% of drugs):
G Protein-Coupled Receptors (GPCRs): ~40% (e.g., beta-adrenergic receptors)
Ligand-Gated Ion Channels: ~20% (e.g., nicotinic acetylcholine receptor)
Catalytic Receptors: ~15% (e.g., Receptor Tyrosine Kinases like the insulin receptor)
Nuclear Receptors: ~10-15% (e.g., glucocorticoid receptors)
2. Non-Receptor Drug Targets (35-40% of drugs):
Enzymes: ~25-30% (e.g., ibuprofen inhibiting COX enzymes)
Transporters: ~10-15% (e.g., SSRIs inhibiting serotonin transporters)
Transporters
Key Functions of Non-Receptor Drug Targets
Move Substances Across Membranes:
Transporters facilitate the selective passage of ions and small molecules across cellular membranes, ensuring that essential nutrients enter the cell while waste products are removed. This is crucial for maintaining cellular homeostasis and normal physiological functions, as well as for nutrient absorption and waste elimination in the body.
Inhibit CNS Transporters to Control Neurotransmitter Levels:
Many transporters are involved in the regulation of neurotransmitter levels in the central nervous system (CNS). For instance, serotonin transporters play a key role in reuptake of serotonin from the synaptic cleft. By inhibiting these transporters with drugs like SSRIs, the levels of neurotransmitters can be increased, which is beneficial in treating mood disorders.\
Affect Distribution, Elimination, and Toxicity of Drugs:
Non-receptor drug targets significantly influence pharmacokinetics—the study of how drugs move through the body. Transporters can determine the rate at which a drug enters tissues, its distribution throughout the body, how quickly it is metabolized, and how effectively it is eliminated. Additionally, improper functioning of these transporters can lead to drug toxicity, as accumulation of toxic substances can occur if they are not efficiently removed from the system.
Responsible for development of resistance seen with some anticancer, antiviral, antibacterial and anticonvulsant drugs as they actively pump drugs out of target cells.
Transporter Families
ABC Transporters: Use ATP hydrolysis for active transport (e.g. MDR1).
ABC Transporters
Definition: ATP-Binding Cassette (ABC) transporters are a large family of membrane transport proteins that utilize the energy derived from ATP hydrolysis to translocate various substrates across cellular membranes.
Key Characteristics of ABC Transporters:
Mechanism of Action:
ABC transporters function by binding ATP, which is hydrolyzed to ADP and inorganic phosphate during the transport cycle. This process provides the energy needed for the conformational changes required to move substrates against their concentration gradient.
Substrates:
These transporters can transport a wide variety of substrates, including:
Ions
Lipids
Drugs (e.g., anticancer agents)
Steroids
Structure:
ABC transporters typically consist of two main domains:
Transmembrane domains (TMDs): These span the lipid bilayer to form the pathway through which substrates pass.
Nucleotide-binding domains (NBDs): These bind and hydrolyze ATP, playing a crucial role in energy transduction.
The combination of these domains allows ABC transporters to perform their active transport functions.
Examples:
MDR1 (Multi-Drug Resistance Protein 1):
Also known as P-glycoprotein, MDR1 is perhaps the most well-known ABC transporter. It is responsible for the efflux of various drugs out of cells, contributing to multi-drug resistance in cancer therapy.
Increased expression of MDR1 in cancer cells can significantly limit the effectiveness of chemotherapeutic agents.
Clinical Importance:
ABC transporters are crucial in pharmacology, as they influence drug absorption, distribution, metabolism, and excretion (ADME). Their activity can lead to both therapeutic failures and adverse drug reactions by altering drug bioavailability and sensitivity.
Understanding the function of ABC transporters in disease states can aid in developing strategies to overcome drug resistance, such as co-administering transporter inhibitors to enhance therapy efficacy.
Conclusion
ABC transporters are essential for maintaining cellular homeostasis and play a significant role in pharmacotherapy, particularly concerning drug resistance. Research on these transporters continues to be vital for developing effective treatment strategies.
SLC Transporters: Use concentration gradients for transport of substrates.
Definition: SLC (Solute Carrier) transporters are a large family of membrane proteins responsible for the transport of various substrates across cell membranes using concentration gradients. They play a crucial role in maintaining cellular homeostasis and facilitating the movement of essential nutrients.
Key Characteristics of SLC Transporters:
Mechanism of Action:
SLC transporters typically utilize concentration gradients to drive the transport of substrates. They can operate through facilitated diffusion, where substrates move down their concentration gradient, or through secondary active transport, where the energy derived from one substrate's concentration gradient is used to transport another substrate against its gradient.
Types of Transport:
Uniporters: Transport a single type of substrate across the membrane, moving it down its concentration gradient.
Symporters: Move two or more substrates in the same direction across the membrane, often using the gradient of one substrate to drive the transport of another.
Antiporters: Exchange one substrate for another, where one substrate moves into the cell while another moves out.
Substrates:
SLC transporters can transport a wide variety of substrates, including:
Ions: Such as sodium (Na+), potassium (K+), and chloride (Cl-).
Small molecules: Such as glucose, amino acids, and various metabolites.
Neurotransmitters: Involved in synaptic transmission, such as dopamine and serotonin.
Examples of SLC Transporters:
SLC1A: Glutamate transporters that remove the neurotransmitter glutamate from the synaptic cleft, preventing excitotoxicity in the brain.
SLC2A (GLUT transporters): Facilitate the transport of glucose across the plasma membrane, essential for cellular metabolism.
SLC6A: Family of neurotransmitter transporters that reuptake neurotransmitters from the synaptic cleft, including serotonin (SERT) and norepinephrine (NET) transporters, both targeted by antidepressants.
Clinical Importance:
SLC transporters are vital in pharmacology as they regulate the availability of drugs and nutrients. Their function impacts drug absorption, distribution, metabolism, and excretion (ADME).
Alterations in the function or expression of SLC transporters can lead to various disease states, including metabolic disorders, neurological conditions, and drug resistance.
Understanding the roles of SLC transporters can inform drug development, particularly in designing effective medications targeting specific transport pathways to enhance therapeutic outcomes or minimize side effects.
Conclusion
SLC transporters are essential for nutrient transport and cellular signaling, and research into their mechanisms continues to be significant for understanding pharmacokinetics and developing new therapeutic strategies.
Enzymes as Drug Targets
Enzymes lower activation energy of reactions, enabling catalysis.
Most drugs targeting enzymes are inhibitors.
Examples
Ibuprofen: Inhibits COX 1 and 2 enzymes to reduce production of inflammatory mediators.
Neostigmine: Inhibits acetylcholine esterase to boost acetylcholine levels.
Receptor Drug Targets Characteristics
Receptors Bind: They translate chemical signals to biological responses.
Examples:
Ligand-gated ion channels
G protein-coupled receptors
Catalytic receptors
Nuclear receptors
Receptor Drug Targets Characteristics
Receptors Bind: They are specialized proteins that detect specific chemical signals (ligands) and translate these signals into biological responses within cells. This process is essential for cellular communication and function.
Types of Receptor Drug Targets:
Ligand-Gated Ion Channels:
Definition: These receptors have a pore that opens or closes in response to the binding of a ligand, allowing ionic flow across the membrane.
Function: They mediate rapid responses to neurotransmitters or other signaling molecules.
Example: The nicotinic acetylcholine receptor opens to allow Na+ ions into muscle cells, triggering contraction.
G Protein-Coupled Receptors (GPCRs):
Definition: GPCRs are characterized by seven transmembrane helices and are coupled to intracellular G proteins.
Function: They initiate signal transduction pathways that affect various physiological processes, from sensory perception to immune response.
Example: The beta-adrenergic receptor, which mediates the effects of epinephrine, impacting heart rate and bronchial dilation.
Catalytic Receptors:
Definition: These receptors possess intrinsic enzyme activity, typically activating when a ligand binds, which often leads to dimerization and subsequent phosphorylation of target proteins.
Function: They are involved in signaling pathways critical for cellular functions such as growth and metabolism.
Example: The insulin receptor, which activates a cascade affecting glucose uptake and metabolism.
Nuclear Receptors:
Definition: Located in the cytoplasm or nucleus, these receptors bind to steroid hormones or other lipophilic substances, resulting in changes in gene expression.
Function: They regulate transcription of specific genes, thus influencing cellular function and homeostasis.
Example: Thyroid hormone receptors, which regulate metabolism by affecting genes involved in energy homeostasis.
Types of Receptors
Ligand-Gated Ion Channels
Induced conformational changes allow ion flow (Na+, K+, Ca2+).
Example: Nicotinic acetylcholine receptor.
Ligand-Gated Ion Channels
Definition: Ligand-gated ion channels are a class of transmembrane proteins that facilitate the passage of ions across the cellular membrane in response to the binding of a specific ligand, such as a neurotransmitter. They play crucial roles in various physiological processes, including signal transmission in neurons and muscle contraction.
Mechanism of Action:
Ligand Binding: The process begins when an endogenous ligand (like a neurotransmitter) binds to the receptor site on the extracellular portion of the ion channel.
Conformational Change: This binding induces a conformational change in the channel protein, resulting in the opening of the channel's pore.
Ion Flow: Once the channel is open, ions such as sodium (Na+), potassium (K+), or calcium (Ca2+) can flow through the channel, moving down their respective electrochemical gradients.
Cellular Response: The flow of ions leads to rapid changes in the membrane potential, which can trigger various cellular responses, including the generation of action potentials in neurons or muscle contraction in muscle cells.
Key Characteristics:
Rapid Response: Ligand-gated ion channels mediate fast synaptic transmission, with activation times typically occurring within milliseconds of ligand binding.
Specificity: Each channel is selective for specific ions based on size and charge, ensuring precise control of ion flow and subsequent cellular processes.
Desensitization: Prolonged exposure to a ligand can lead to desensitization, where the channel becomes less responsive to the ligand even in its presence. This is a mechanism that helps terminate the signal after it has been initiated.
Examples of Ligand-Gated Ion Channels:
Nicotinic Acetylcholine Receptor (nAChR):
Role: This receptor is crucial for neurotransmission at the neuromuscular junction, facilitating synaptic transmission between motor neurons and skeletal muscle cells.
Function: When acetylcholine binds to nAChRs, it causes an influx of Na+ ions, leading to depolarization of the muscle cell membrane and initiating muscle contraction.
GABA_A Receptor:
Role: This receptor mediates inhibitory neurotransmission in the central nervous system.
Function: Binding of gamma-aminobutyric acid (GABA) to GABA_A receptors opens chloride (Cl-) channels, allowing Cl- ions to enter the neuron, leading to hyperpolarization and decreased neuronal excitability.
Glutamate Receptors (e.g., AMPA and NMDA):
Role: These receptors are essential for synaptic plasticity and cognitive processes such as learning and memory.
Function: Activation by glutamate allows Na+ (and Ca2+ for NMDA receptors) influx, contributing to depolarization and synaptic strength enhancement in excitatory synapses.
Clinical Significance:
Pharmacological Targets: Ligand-gated ion channels are significant drug targets for a variety of conditions, including neurological disorders, muscle diseases, and cardiac issues. Many medications, such as anesthetics and antiepileptic drugs, exert their effects by modulating these channels.
Pathological Conditions: Dysfunction of ligand-gated ion channels can lead to numerous diseases, including epilepsy, chronic pain, and myasthenia gravis, highlighting their importance in both normal physiology and pathology.
Conclusion:
Ligand-gated ion channels are vital components of cellular communication, enabling rapid responses to chemical signals. Understanding their mechanisms and functions aids in developing therapeutic strategies targeting various diseases and conditions.
G Protein-Coupled Receptors (GPCRs)
Composed of seven transmembrane helices.
Large family: over 800 types in human genome.
G Protein-Coupled Receptors (GPCRs)
Definition: G Protein-Coupled Receptors (GPCRs) are a large family of cell surface receptors that play a critical role in cellular signaling. They are characterized by their seven transmembrane α-helices and are responsible for mediating various physiological processes in response to diverse stimuli.
Structure:
Transmembrane Domains: GPCRs span the cell membrane with seven hydrophobic regions, each representing a transmembrane helix. These helices form a pocket that can interact with ligands.
Extracellular N-terminus: This region is involved in ligand binding. It contains specific sites that recognize and bind to different ligands, such as hormones, neurotransmitters, and sensory stimuli.
Intracellular C-terminus: This part of the GPCR interacts with intracellular signaling molecules, primarily G proteins. The activation of GPCRs triggers signaling cascades inside the cell.
Mechanism of Action:
Ligand Binding: The receptor undergoes a conformational change upon the binding of an extracellular ligand, which activates the receptor.
G Protein Activation: The activated receptor interacts with a G protein, which consists of three subunits (alpha, beta, and gamma). The binding triggers the exchange of GDP for GTP on the alpha subunit, activating it.
Signal Transduction: The GTP-bound alpha subunit dissociates from the beta and gamma subunits and interacts with downstream effectors such as enzymes or ion channels, initiating intracellular signaling pathways.
Termination: The G protein's intrinsic GTPase activity hydrolyzes GTP to GDP, leading to the reassociation of the G protein subunits and deactivation of the signal. This process allows for signal termination and resets the receptor for future ligand binding.
Types of GPCRs:
Class A (Rhodopsin-like): This is the largest group, including many receptors for neurotransmitters (e.g., adrenergic receptors).
Class B (Secretin-like): These receptors predominantly respond to peptide hormones, such as glucagon.
Class C (Metabotropic Glutamate/Calcium-sensing receptors): These receptors engage various ligands, including glutamate and calcium ions.
Functions:
Sensory Perception: GPCRs mediate sensory signals such as vision, taste, and smell. For example, rhodopsin is a GPCR that detects light.
Neurotransmission: Many neurotransmitter receptors, including dopamine and serotonin receptors, belong to the GPCR family and are key players in mental health and neurological disorders.
Hormonal Regulation: GPCRs play a vital role in regulating diverse physiological processes like stress responses, metabolism, and cardiovascular function.
Clinical Significance:
Drug Targets: GPCRs represent a significant proportion of drug targets, with approximately 30-50% of all marketed pharmaceuticals acting on GPCRs. This includes antihistamines, beta blockers, and opioids.
Pathway Dysregulation: Abnormal signaling through GPCRs can lead to various diseases, including cancer, cardiovascular diseases, and obesity, making understanding their function crucial for pharmacological development.
Conclusion:
G Protein-Coupled Receptors are essential components of signaling pathways that regulate numerous physiological functions. Their diverse roles and clinical significance make them a focal point in drug discovery and therapeutic interventions.
Catalytic Receptors
Dimerize upon ligand binding and have intrinsic enzyme activity.
Types of Catalytic Receptors
Receptor Tyrosine Kinase (RTK)
Receptor Serine/Threonine Kinase
Cytokine Receptors
Receptor Guanylyl Cyclases
Receptor Protein Tyrosine Phosphatases
Catalytic Receptors
Definition: Catalytic receptors are a class of cell membrane receptors that possess intrinsic enzyme activity and can trigger cellular responses upon binding with a specific ligand. Unlike other receptors that only transmit signals, these receptors initiate biochemical reactions inside the cell.
Mechanism of Action:
Dimerization: Upon ligand binding, two identical or similar receptor proteins often come together (dimerize), which is essential for activating the enzymatic function.
Intrinsic Enzyme Activity: Catalytic receptors have enzymatic activity directly associated with their cytoplasmic domain, allowing them to catalyze reactions immediately following activation. For example, when a ligand binds, certain receptors have the ability to phosphorylate themselves or other proteins, a key step in signal transduction.
Signal Transduction: The phosphorylation of proteins activates signaling pathways that regulate various cellular processes such as metabolism, growth, and differentiation.
Types of Catalytic Receptors:
Receptor Tyrosine Kinases (RTKs):
Function: These receptors phosphorylate tyrosine residues on themselves (autophosphorylation) and on downstream signaling proteins.
Examples: Insulin Receptor, Epidermal Growth Factor Receptor (EGFR). RTKs play vital roles in cellular growth, differentiation, and metabolism. Misregulation can lead to cancers.
Receptor Serine/Threonine Kinases:
Function: Similar to RTKs, these receptors phosphorylate serine and threonine residues on target proteins.
Examples: Transforming Growth Factor-beta (TGF-β) receptors, which are crucial in regulating cell growth and differentiation processes and signaling within the immune system.
Cytokine Receptors:
Function: These receptors do not have intrinsic kinase activity but recruit associated kinases (like Janus kinases or JAKs) upon ligand binding, which then phosphorylate downstream proteins.
Examples: Interleukin receptors play an essential role in immune responses and can alter gene expression through the JAK-STAT signaling pathway.
Receptor Guanylyl Cyclases:
Function: Upon ligand binding, these receptors convert GTP (guanosine triphosphate) into cGMP (cyclic guanosine monophosphate), a secondary messenger vital for signaling in cardiovascular function.
Examples: Atrial Natriuretic Peptide (ANP) receptor is involved in regulating blood pressure and volume.
Receptor Protein Tyrosine Phosphatases (RPTPs):
Function: Opposite to kinases, these receptors remove phosphate groups from tyrosine residues on proteins, serving to turn down signaling pathways.
Examples: RPTPμ and RPTPσ play roles in cellular communication and developmental signaling pathways, particularly in neuronal systems.
Clinical Significance:
Drug Targets: Many catalytic receptors are targets for cancer therapy and other diseases. For instance, RTKs are often mutated in many cancers, making them key therapeutic targets for inhibitors, such as imatinib, which targets the BCR-ABL fusion protein in chronic myelogenous leukemia (CML).
Pathway Dysregulation: Alterations in catalytic receptor function can lead to diseases, including cancers, metabolic disorders, and immune system dysfunctions.
Conclusion:
Catalytic receptors are crucial for translating extracellular signals into cellular actions, and their diverse functionalities contribute significantly to various physiological processes. Understanding these receptors' mechanisms provides critical insights for therapeutic developments in managing related health conditions.
Nuclear Receptors
Bind endogenous ligands and regulate gene transcription after conformational changes.
Exist as either
Class I: Hormones like glucocorticoids.
Class II: Lipid ligands like thyroid hormones.
Nuclear Receptors
Definition: Nuclear receptors are a class of intracellular proteins that bind to specific endogenous ligands (such as hormones, vitamins, and other signaling molecules) and, upon activation, regulate gene transcription in the nucleus of the cell. They play a crucial role in various physiological processes including metabolism, development, and homeostasis.
Mechanism of Action:
Ligand Binding: When an endogenous ligand (such as a hormone) diffuses across the cell membrane, it binds to the ligand-binding domain of the nuclear receptor, producing a conformational change in the receptor.
Translocation to the Nucleus: After binding, many nuclear receptors undergo a conformational change that promotes their translocation from the cytoplasm to the cell nucleus.
Dimerization: Certain nuclear receptors form dimers (either homodimers or heterodimers) with other nuclear receptors, which is often necessary for binding to the DNA.
DNA Binding: The activated nuclear receptor complex binds to specific sequences of DNA known as response elements located in the promoter regions of target genes. This interaction typically occurs in the form of direct or indirect binding to hormone response elements (HREs).
Transcription Regulation: Once bound to the DNA, the receptor activates or represses the transcription of specific genes by recruiting co-regulatory proteins, which can be co-activators or co-repressors, thus influencing the transcription of mRNA and subsequent protein synthesis.
Types of Nuclear Receptors:
Class I Nuclear Receptors:
Definition: These receptors primarily respond to steroid hormones. They are located in the cytoplasm and, upon ligand binding, translocate to the nucleus for gene activation.
Examples: Glucocorticoid Receptor (GR), Estrogen Receptor (ER), Testosterone Receptor (AR).
Function: Class I receptors are involved in regulating metabolism, immune response, and reproductive processes by modulating gene expression.
Class II Nuclear Receptors:
Definition: These receptors are generally located in the nucleus in the absence of ligand and directly interact with DNA to regulate transcription, often working as heterodimers with retinoid X receptors (RXR).
Examples: Thyroid Hormone Receptor (TR), Retinoic Acid Receptor (RAR), and Peroxisome Proliferator-Activated Receptor (PPAR).
Function: Class II receptors are key regulators of development, metabolism, and cellular differentiation. They act in response to lipid ligands like thyroid hormones, retinoids, and fatty acids, influencing processes such as energy metabolism and growth.
Clinical Significance:
Drug Targets: Nuclear receptors are important pharmacological targets due to their central role in regulating gene expression involved in various diseases. Drugs like glucocorticoids (for inflammation) or selective estrogen receptor modulators (SERMs) are designed to target specific nuclear receptors.
Pathological Conditions: Dysfunction in nuclear receptor signaling can lead to various disorders, including metabolic syndromes, endocrine diseases, and cancers. For example, mutations in the thyroid hormone receptor can cause developmental disorders and hypothyroidism.
Conclusion:
Nuclear receptors are critical for mediating cellular responses to endogenous signals, and their ability to regulate gene expression allows them to influence a wide array of physiological functions. Understanding these receptors not only provides insight into fundamental biological processes but also aids in the development of targeted therapies for various diseases.
Class 1 nuclear receptors:
Inactive form: present in the cytoplasm associated with a heat-shock protein. They mainly bind to endocrine ligands and act as homodimers. The HSP help the receptor to stabilise the correct conformation of the receptor for ligand binding.
Activation:
Ligand binding causes a conformational change that results in the dissociation of the receptor from HSP complexes and translocation into the nucleus
In the nucleus, it binds to co-activators, then bind to DNA, affecting gene expression
Class 2 nuclear receptors
Inactive form: present in the nucleus associated with a co-repressor protein. They mainly bind to lipid ligands and act as heterodimers.
Activation:
Ligand binding causes a conformational change that results in the dissociation of the corepressors and the binding of co-activators
Receptor binds to DNA, affecting gene expression
Time Scales of Receptor Signalling
Ligand-Gated Ion Channels: Milliseconds (e.g., nicotinic ACh receptor).
G Protein-Coupled Receptors: Seconds-Hours (e.g., muscarinic ACh receptor).
Catalytic Receptors and Nuclear Receptors: Hours (gene regulation).
Conclusion
By the end of this lecture, you should be able to:
Explain the concept of receptors.
Describe their roles and major protein families.
Recognize the time scales for their action.
ABC Transporters Mechanism
Definition: ATP-Binding Cassette (ABC) transporters are a large family of membrane transport proteins that utilize the energy derived from ATP hydrolysis to translocate various substrates across cellular membranes.
Mechanism of Action:
Binding of Substrate:
ABC transporters start the transport process by binding to their substrate (which could be ions, lipids, drugs, etc.) at specific binding sites located within their structure.
ATP Binding:
The transport activity requires the binding of ATP to the nucleotide-binding domains (NBDs) of the transporter. Two NBDs are typically found in ABC transporters, enabling them to hydrolyze ATP for energy.
Conformational Change:
The hydrolysis of ATP (converting ATP to ADP and inorganic phosphate) induces a conformational change in the transporter. This change alters the shape of the protein and creates a pathway for the substrate to move across the membrane.
Transport of the Substrate:
The conformational change effectively moves the substrate from one side of the membrane to the other. The substrate is released into the extracellular space or the cytoplasm, depending on the direction of transport.
Resetting the Transporter:
After the substrate is released, the transporter undergoes another conformational change to reset itself to its original state, ready to bind another substrate and repeat the cycle. This reset can involve the binding of another ATP molecule to reactivate the transport process.
Key Characteristics:
Energy-Dependent: The process is energy-dependent, requiring the hydrolysis of ATP, making it distinct from other transport mechanisms that might rely on concentration gradients alone.
Substrate Specificity: ABC transporters can transport a broad range of substrates, and their specificity can vary depending on the individual transporter and the type of substrate.
Role in Drug Resistance: Some ABC transporters, such as MDR1 (multi-drug resistance protein), are involved in the efflux of drugs from cancer cells, contributing to multi-drug resistance in cancer therapy.
Clinical Significance:
Pharmacology: Understanding the function of ABC transporters is critical in drug development, as they influence the absorption, distribution, metabolism, and excretion (ADME) of many drugs.
Disease Association: Abnormalities in ABC transporter function can lead to various pathologies, including drug resistance in cancer treatments, and can affect the pharmacokinetics of therapies used in diseases.
Conclusion
ABC transporters are essential for maintaining cellular homeostasis and play a significant role in pharmacotherapy, particularly concerning drug resistance. Research on these transporters continues to be vital for developing effective treatment strategies.
SLC Transporters Mechanism
Definition: SLC (Solute Carrier) transporters are a large family of membrane proteins responsible for the transport of various substrates across cell membranes using concentration gradients. They are vital for maintaining cellular homeostasis and facilitating the movement of essential nutrients.
Mechanism of Action:
Substrate Binding:
SLC transporters begin the transport process by binding to a specific substrate (such as ions, glucose, or amino acids) at their binding sites, exposing the transporter to extracellular surroundings.
Transport Types:
Uniporters: Transport a single type of substrate across the membrane, moving it down its concentration gradient.
Symporters: Move two or more substrates in the same direction across the membrane, using the gradient of one substrate to drive the transport of another.
Antiporters: Exchange one substrate for another, where one substrate moves into the cell while another moves out, maintaining the balance of substrates within the cell.
Conformational Change:
Once the substrate binds, a conformational change occurs in the transporter protein, allowing the substrate to be translocated across the membrane.
This change effectively opens the channel to the interior of the cell, enabling the substrate to pass through.
Release of Substrate:
Upon reaching the other side of the membrane, the substrate is released into the cytoplasm or extracellular space, depending on the transport direction.
Resetting the Transporter:
After the substrate is released, the transporter reverts to its original conformation, ready to bind another substrate and repeat the cycle, maintaining the efficiency of transport.
Key Characteristics:
Concentration Gradient Use: SLC transporters utilize the existing concentration gradients to facilitate the passive or active transport of substrates, making their mechanisms crucial for nutrient uptake and cellular function.
Specificity: The specificity of SLC transporters allows them to target particular substrates essential for cellular metabolism and signaling.
Conclusion
SLC transporters are integral to cellular transport processes, utilizing concentration gradients to move substrates across membranes, thus ensuring cellular homeostasis and proper function of various biological processes.
Mechanism of Receptor Tyrosine Kinases (RTKs)
Ligand Binding: The mechanism begins when a ligand (e.g., a growth factor) binds to the extracellular domain of the RTK, leading to a conformational change in the receptor.
Dimerization: This conformational change promotes the dimerization of two RTK molecules— either two identical receptors or different types of RTKs—bringing their intracellular domains into close proximity.
Autophosphorylation: Once dimerized, the cytoplasmic kinase domains of the RTKs phosphorylate tyrosine residues within their own intracellular regions. This process of autophosphorylation increases the kinase activity of the receptor and creates docking sites for downstream signaling proteins.
Recruitment of Signaling Proteins: The phosphorylated tyrosine residues serve as binding sites for various signaling proteins, which contain phosphotyrosine-binding domains (such as SH2 or PTB domains).
Signal Transduction: The recruited signaling proteins become activated and form signaling cascades that propagate the signal inside the cell, leading to various biological responses, including cellular growth, differentiation, or metabolism.
Termination: The activity of the RTK signaling pathway is eventually terminated through dephosphorylation by specific phosphatases or through internalization and degradation of the receptor, preventing overstimulation and maintaining cellular homeostasis.
MCQ
Pharmacology Quiz
Multiple Choice Questions (Select the single best answer):
Which of the following statements accurately distinguishes between endogenous agonists, exogenous agonists, and antagonists in the context of receptor pharmacology? a) Endogenous agonists are always hormones, while exogenous agonists are always neurotransmitters, and antagonists bind without eliciting a response. b) Endogenous agonists and exogenous agonists both bind to a receptor and activate it, leading to a cellular response, whereas antagonists bind to the receptor and prevent agonist binding, thus blocking the response. c) Antagonists always have a higher affinity for the receptor than agonists, ensuring they effectively block the receptor's activation. d) Exogenous agonists are produced within the body, while endogenous agonists are introduced externally to mimic the effects of naturally occurring ligands.
Considering the three stages of cell signalling initiated by receptor activation, which of the following best describes the process of transduction? a) The initial binding of a hormone or neurotransmitter to a receptor on the cell membrane or inside the cell. b) The stimulation of effector proteins, leading directly to a biological response such as muscle contraction or secretion. c) The transmission of information across the cell membrane via receptor interaction with intracellular proteins or molecules, initiating a cascade of downstream events. d) The termination of the cellular response through the degradation of the ligand or desensitization of the receptor.
Which of the following protein families encompasses the largest number of identified drug targets and is characterised by seven transmembrane helices? a) Ligand-gated ion channels. b) Catalytic receptors. c) G protein-coupled receptors (GPCRs). d) Nuclear receptors.
Which of the following statements accurately describes the mechanism of action of ligand-gated ion channels? a) They activate intracellular enzymes upon ligand binding, leading to downstream signalling cascades. b) Ligand binding induces a conformational change that directly allows the flow of ions across the cell membrane, resulting in a rapid change in membrane potential. c) They dimerise upon ligand binding and initiate phosphorylation cascades through intrinsic kinase activity. d) They translocate to the nucleus upon ligand binding and directly influence gene transcription.
The nicotinic acetylcholine receptor (nAChR) is a classic example of a ligand-gated ion channel. Which of the following is a key characteristic of its function? a) It primarily mediates inhibitory signals in the central nervous system by allowing the influx of chloride ions. b) Its activation by acetylcholine leads to the opening of a channel permeable to cations such as Na+, K+, and sometimes Ca2+, resulting in an excitatory postsynaptic potential. c) It is a G protein-coupled receptor that indirectly modulates ion channel activity through second messengers. d) It exhibits very slow kinetics, leading to prolonged changes in cellular excitability over seconds to minutes.
G protein-coupled receptors (GPCRs) exert their diverse effects through interaction with heterotrimeric G proteins. Which of the following correctly describes the initial step in GPCR signalling upon agonist binding? a) Activation of the receptor leads to the dissociation of the G protein into its alpha, beta, and gamma subunits. b) The agonist directly phosphorylates the intracellular loops of the GPCR, initiating downstream signalling. c) Conformational change in the receptor facilitates the exchange of GDP for GTP on the alpha subunit of the G protein. d) The beta-gamma subunit directly activates adenylyl cyclase, leading to an increase in cAMP levels.
Catalytic receptors, formerly known as enzyme-linked receptors, share a common mechanism involving ligand-induced activation of intrinsic or associated enzymatic activity. Which of the following is a major type of catalytic receptor characterised by intrinsic tyrosine kinase activity? a) Receptor Serine/Threonine Kinases. b) Cytokine Receptors. c) Receptor Tyrosine Kinases (RTKs). d) Receptor Guanylyl Cyclases.
Insulin receptor signalling is a prominent example of Receptor Tyrosine Kinase (RTK) function. What is a key initial event following insulin binding to its receptor? a) Activation of associated G proteins leading to phospholipase C activation. b) Dimerisation of the receptor subunits and subsequent autophosphorylation of tyrosine residues in the intracellular domain. c) Translocation of the receptor-ligand complex to the nucleus to directly influence gene transcription. d) Conformational change in the receptor that directly opens an associated ion channel.
Nuclear receptors represent a class of intracellular receptors that primarily regulate gene transcription. Which of the following is a distinguishing characteristic of Class I nuclear receptors? a) They primarily bind to lipid-soluble ligands like thyroid hormone and retinoic acid. b) They function predominantly as heterodimers with the Retinoid X Receptor (RXR) in the nucleus. c) They are often found in the cytoplasm associated with heat shock proteins (HSPs) in their inactive state and form homodimers upon ligand binding and HSP dissociation before translocating to the nucleus. d) Their ligands typically have low affinity for the receptor compared to Class II nuclear receptors.
Which of the following correctly describes the mechanism by which Class II nuclear receptors influence gene transcription? a) Upon ligand binding, they directly activate associated kinase enzymes that phosphorylate transcription factors. b) They exist as heterodimers, commonly with RXR, in the nucleus, and ligand binding induces a switch from binding to corepressors to binding to coactivators, thereby modulating gene expression. c) They translocate from the cytoplasm to the nucleus as monomers upon ligand binding and directly bind to DNA response elements. d) Their primary mechanism involves altering mRNA stability rather than transcriptional initiation.
Transporters and enzymes are classified as non-receptor drug targets because: a) They are located intracellularly and do not interact with the cell surface. b) They do not bind to endogenous molecules to initiate an intracellular signalling pathway. c) They are only targeted by exogenous molecules and not involved in normal physiological processes. d) Their primary function is structural rather than functional.
Which of the following statements accurately describes the function of ABC transporters? a) They utilise the energy from ion gradients to move substrates across cell membranes. b) They are a family of membrane proteins that use ATP hydrolysis to actively transport a wide variety of substrates across cellular membranes, often against their concentration gradients. c) They primarily facilitate the passive diffusion of lipophilic molecules across the lipid bilayer. d) They are exclusively involved in the uptake of nutrients into cells.
SLC transporters facilitate the movement of substrates across cell membranes. Which of the following is a key characteristic that distinguishes them from ABC transporters? a) SLC transporters directly utilise ATP hydrolysis as their primary energy source. b) SLC transporters are only involved in the efflux of drugs from cells. c) SLC transporters often utilise the energy derived from the movement of one or more molecules down their electrochemical gradient to transport another solute against its gradient (secondary active transport). d) SLC transporters primarily transport large macromolecules across the cell membrane.
Enzymes are important drug targets, with many drugs acting as inhibitors. What is the primary mechanism by which enzyme inhibitors exert their pharmacological effect? a) They increase the activation energy required for the enzymatic reaction to occur. b) They bind to the enzyme's active site or another regulatory site, preventing the enzyme from efficiently catalysing its reaction, thereby reducing the formation of products. c) They promote the degradation of the enzyme, reducing the overall enzyme concentration. d) They allosterically activate the enzyme, leading to the production of alternative metabolic products.
Considering the different receptor families, which of the following generally exhibits the fastest time scale for inducing cellular changes upon ligand binding? a) Nuclear receptors. b) Catalytic receptors (e.g., Receptor Tyrosine Kinases). c) G protein-coupled receptors. d) Ligand-gated ion channels.
Open Ended Questions:
Compare and contrast the general mechanisms of signal transduction initiated by G protein-coupled receptors and Receptor Tyrosine Kinases. In your answer, discuss the initial events following ligand binding, the involvement of intermediate signalling molecules, and the ultimate cellular responses that can be elicited by each receptor type.
Explain the significance of non-receptor drug targets, specifically transporters and enzymes, in pharmacology. Provide examples of how drugs targeting these molecules can modulate physiological processes and discuss the implications for drug development and therapeutic applications.
Answers and Justifications:
Multiple Choice Answers:
b).
Correct: Option b accurately describes the function of endogenous agonists (naturally occurring activators), exogenous agonists (external molecules mimicking endogenous agonists), and antagonists (molecules that block agonist effects).
Incorrect a): Endogenous agonists are not exclusively hormones, and exogenous agonists are not exclusively neurotransmitters. Antagonists bind and prevent activation, not necessarily without any interaction.
Incorrect c): While some antagonists have high affinity, it's not a universal requirement. Efficacy (the ability to produce a response) is the key difference.
Incorrect d): The definitions of endogenous and exogenous are reversed in this option.
c).
Correct: Transduction is the process where the receptor transmits the signal across the membrane and initiates intracellular signalling pathways.
Incorrect a): This describes reception.
Incorrect b): This describes the response.
Incorrect d): This describes signal termination.
c).
Correct: GPCRs are the largest family of cell surface receptors and are major targets for drug development, characterised by their seven transmembrane helices.
Incorrect a, b, d): While these are also important drug target families, they are not the largest, and they have different structural characteristics.
b).
Correct: Ligand binding to ion channels directly opens or closes the channel pore, allowing ions to flow down their electrochemical gradient, leading to rapid changes in membrane potential.
Incorrect a, c, d): These describe the mechanisms of other receptor families (GPCRs, catalytic receptors, and nuclear receptors, respectively).
b).
Correct: The nAChR is an excitatory channel that opens upon acetylcholine binding, allowing influx of positive ions and causing depolarisation.
Incorrect a): GABA receptors are the primary inhibitory ligand-gated ion channels in the CNS.
Incorrect c): nAChR is a directly gated ion channel, not a GPCR.
Incorrect d): Ligand-gated ion channels generally mediate fast responses.
c).
Correct: Agonist binding to a GPCR induces a conformational change that allows the receptor to interact with the G protein, catalysing the exchange of GDP for GTP on the alpha subunit.
Incorrect a): The G protein subunits dissociate after GTP binding to the alpha subunit.
Incorrect b): While phosphorylation can regulate GPCRs, it's not the initial event upon agonist binding.
Incorrect d): The alpha subunit typically activates adenylyl cyclase (or other effectors), not directly the beta-gamma subunit in this context.
c).
Correct: Receptor Tyrosine Kinases are a major class of catalytic receptors that possess intrinsic tyrosine kinase activity, which is activated upon ligand binding.
Incorrect a, b, d): These are other types of catalytic receptors with different enzymatic activities or associated proteins.
b).
Correct: Insulin binding leads to the dimerisation of the insulin receptor subunits, which activates the intrinsic tyrosine kinase domains, resulting in autophosphorylation.
Incorrect a, c, d): These are not the primary initial events in insulin receptor signalling.
c).
Correct: Class I nuclear receptors, such as steroid hormone receptors, are typically found in the cytoplasm bound to HSPs in their inactive state. Ligand binding causes HSP dissociation, receptor dimerisation, and translocation to the nucleus.
Incorrect a): Class II receptors primarily bind lipid ligands.
Incorrect b): Class I receptors function as homodimers.
Incorrect d): Class I ligands often have high affinity.
b).
Correct: Class II nuclear receptors exist as heterodimers in the nucleus and regulate gene transcription by altering the recruitment of corepressor and coactivator proteins upon ligand binding.
Incorrect a, c, d): These are not the primary mechanisms of Class II nuclear receptor action.
b).
Correct: Non-receptor drug targets like transporters and enzymes do not initiate signalling pathways by binding to endogenous ligands in the same way that classical receptors do.
Incorrect a): While some are intracellular, others are membrane-bound.
Incorrect c): They are involved in crucial physiological processes.
Incorrect d): Their function is primarily catalytic or transport-related.
b).
Correct: ABC transporters are characterised by their use of ATP hydrolysis to actively pump a wide range of substrates across cell membranes.
Incorrect a, c, d): These statements do not accurately describe the key features of ABC transporters.
c).
Correct: SLC transporters often utilise secondary active transport mechanisms, coupling the movement of one substance down its gradient to the movement of another against its gradient.
Incorrect a, b, d): These are incorrect descriptions of SLC transporter function.
b).
Correct: Enzyme inhibitors reduce the rate of enzymatic reactions by binding to the enzyme and interfering with substrate binding or catalysis.
Incorrect a, c, d): These are not the primary mechanisms of enzyme inhibition by most drugs.
d).
Correct: Ligand-gated ion channels mediate rapid changes in membrane potential within milliseconds due to the direct flow of ions.
Incorrect a, b, c): Nuclear receptors typically have the slowest time course (hours) as they involve gene transcription, followed by catalytic receptors (seconds to minutes) and GPCRs (seconds).
Open Ended Answers:
G Protein-Coupled Receptors (GPCRs): Agonist binding to a GPCR induces a conformational change in the receptor. This activated receptor then interacts with a heterotrimeric G protein (comprising alpha, beta, and gamma subunits) located on the intracellular side of the cell membrane. This interaction facilitates the exchange of GDP for GTP on the alpha subunit, causing the G protein to become activated. The activated alpha subunit, and sometimes the beta-gamma complex, then dissociate and can interact with various effector proteins such as adenylyl cyclase or phospholipase C. These effector proteins then generate second messenger molecules like cAMP or IP3 and DAG, which go on to activate downstream protein kinases or ion channels, ultimately leading to a diverse range of cellular responses including changes in metabolism, gene expression, and cellular excitability.
Receptor Tyrosine Kinases (RTKs): Signal transduction by RTKs typically begins with the binding of a ligand (often a growth factor or hormone) to the extracellular domain of the receptor. This binding event promotes receptor dimerisation (the association of two receptor monomers). Dimerisation brings the intracellular tyrosine kinase domains of the two receptor subunits into close proximity, leading to their activation and subsequent autophosphorylation. These phosphorylated tyrosine residues then serve as docking sites for various intracellular signalling proteins with SH2 domains or other phosphotyrosine-binding domains. Recruitment and activation of these adapter proteins and enzymes initiate complex intracellular signalling cascades, often involving the Ras/MAPK pathway or the PI3K/Akt pathway. These pathways ultimately lead to changes in gene expression, cell growth, differentiation, and metabolism.
Comparison: Both GPCRs and RTKs are cell surface receptors that initiate intracellular signalling upon ligand binding. However, GPCRs indirectly activate downstream effectors through G proteins and second messengers, whereas RTKs possess intrinsic enzymatic activity that is directly activated by ligand binding and dimerisation, leading to the recruitment and activation of intracellular signalling molecules. GPCR signalling often leads to faster, more transient responses mediated by second messengers, while RTK signalling can lead to longer-lasting effects involving changes in gene expression and cell growth.
Significance of Non-Receptor Drug Targets (Transporters and Enzymes): Non-receptor drug targets, including transporters and enzymes, are critically significant in pharmacology because they play fundamental roles in maintaining cellular homeostasis, metabolic pathways, and the transport of essential molecules throughout the body. Unlike classical receptors that initiate signalling upon binding endogenous ligands, these targets perform vital functions that can be modulated by exogenous drug molecules to achieve therapeutic effects.
Transporters: Transporters are membrane proteins responsible for the movement of various substances (ions, neurotransmitters, nutrients, drugs) across cell membranes. Drugs targeting transporters can modulate the concentrations of key molecules in specific locations. For example, selective serotonin reuptake inhibitors (SSRIs) inhibit serotonin transporters (SERT), increasing serotonin levels in the synaptic cleft, which is beneficial in treating depression. Inhibiting monoamine transporters in the CNS can control neurotransmitter levels, impacting mood and behaviour. Furthermore, transporters like P-glycoprotein (MDR1) are involved in the pharmacokinetics (absorption, distribution, and elimination) of many drugs and can contribute to drug resistance in cancer cells by actively pumping drugs out of the cells. Targeting these transporters can improve drug efficacy or overcome resistance mechanisms.
Enzymes: Enzymes are biological catalysts that facilitate biochemical reactions by lowering activation energy. Many commonly used drugs target enzymes to inhibit or, less commonly, activate specific metabolic pathways. For instance, ibuprofen inhibits cyclooxygenase (COX) enzymes, reducing the production of inflammatory mediators and alleviating pain and inflammation. Neostigmine inhibits acetylcholinesterase, increasing acetylcholine levels at the neuromuscular junction and improving muscle contraction in conditions like myasthenia gravis. Enzymes are also crucial in drug metabolism, and drugs can inhibit or induce these metabolic enzymes, affecting the pharmacokinetics and pharmacodynamics of other co-administered drugs.
Implications for Drug Development and Therapeutics: The diverse roles of transporters and enzymes make them valuable targets for drug development across a wide range of therapeutic areas. By specifically modulating the activity of these proteins, drugs can achieve targeted effects on physiological processes and disease mechanisms. Understanding the structure, function, and regulation of different transporters and enzymes is crucial for designing selective and effective drugs with minimal off-target effects. Furthermore, considering the role of transporters in drug disposition and resistance is essential for optimising drug delivery and overcoming treatment failures. The development of drugs targeting non-receptor proteins has significantly expanded the pharmacological arsenal and continues to be a major focus in drug discovery research.